基于FDG-PET的影像组学特征可预测原发性胶质瘤的增殖活性
该回顾性研究纳入123例经组织病理学确诊的原发性胶质瘤患者,随机分为训练队列(n=82)和验证队列(n=41),从FDG-PET的SUV图中提取1561个影像组学特征并构建影像组学特征、临床特征及融合特征三种预测模型,以Ki-67指数为参考标准。影像组学特征在训练队列和验证队列的准确率分别为81.7%和73.2%,AUC分别为0.88和0.76;临床特征和融合特征在训练队列中表现相当,但根据验证队列结果判断存在过拟合。Ki-67指数和影像组学特征均可将患者分为两个不同的预后组,且各预后组内差异无统计学意义。
要点
- 基于FDG-PET的影像组学特征在验证队列预测胶质瘤Ki-67增殖活性的AUC为0.76、准确率为73.2%。
- Ki-67指数和影像组学特征均可将患者分为两个不同的预后组,组内差异无统计学意义。
- 临床特征和融合特征在验证队列中判断为过拟合,性能不及影像组学特征。
核心结论
- 基于18F-FDG-PET的影像组学特征似乎有望用于无创评估胶质瘤增殖活性并辅助预测患者预后。
研究设计与样本
- 回顾性研究,共纳入123例经组织病理学确诊的原发性胶质瘤患者,随机分为训练队列(n=82)和验证队列(n=41)。
- 以免疫组化Ki-67指数定义肿瘤增殖活性,基于FDG-PET生成SUV图并提取1561个影像组学特征。
- 通过依次应用三种算法筛选影像组学特征,构建影像组学特征、临床特征和融合特征三种预测模型,采用受试者工作特征(ROC)曲线分析评估预测性能。
诊断标准与关键数值
- 最终筛选出9个影像组学特征构建影像组学特征,在训练队列的准确率为81.7%、AUC为0.88,在验证队列的准确率为73.2%、AUC为0.76。
- 临床特征和融合特征在训练队列中表现相当,但根据验证队列结果判断存在过拟合。
- Ki-67指数和影像组学特征均可将患者分为两个不同的预后组,各预后组内差异无统计学意义。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To investigate a radiomics method based on 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET) to non-invasively evaluate proliferative activity in gliomas.
MATERIALS AND METHODS: A total of 123 patients with histopathologically confirmed primary glioma were reviewed retrospectively and assigned randomly into the primary cohort (n=82) and validation cohort (n=41). Tumour proliferative activity was defined by the Ki-67 index based on immunohistochemistry. Standard uptake value (SUV) maps were generated, and 1,561 radiomics features were extracted. Radiomics features were selected through the sequential application of three algorithms. Three predictive signatures were generated: a radiomics signature, a clinical signature, and a fusion signature. The predictive performances were evaluated by receiver operating characteristic (ROC) curve analysis, and patient prognoses were stratified based on the Ki-67 index and the signature with the most reliable performance.
RESULTS: Nine radiomics features were selected to construct the radiomics signature that achieved an accuracy of 81.7% and 73.2% and an area under the curve (AUC) of 0.88 and 0.76 in the primary cohort and the validation cohort, respectively. The clinical signature and fusion signature demonstrated comparable performance in the primary cohort but were over-fitted judging from the result in the validation cohort. Both the Ki-67 index and the radiomics signature could stratify patients into two distinctive prognostic groups, and the difference within each prognostic group was not statistically significant.
CONCLUSION: Radiomics signature based on 18F-FDG-PET is a promising method for the non-invasive measurement of glioma proliferative activity and facilitates the prediction of patient prognoses.
引用
- Kong Z, Li J, Liu Z, et al. Radiomics signature based on FDG-PET predicts proliferative activity in primary glioma. Clin Radiol. 2019. PMID: 31376917. doi:10.1016/j.crad.2019.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。